Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients (HELP-IPF)

14 april 2022 uppdaterad av: Centre Hospitalier Universitaire Dijon

Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disease characterized by a progressive and irreversible deterioration in respiratory function, resulting in impaired quality of life (QoL) and patient dependence.

The factors involved in the alteration of QoL in these patients are the physical symptoms related to fibrosis (dyspnea, cough, fatigue) and psychological symptoms (anxiety and depression) as well as social, relational and financial factors, the experience of the disease and disability, the time required for diagnosis, the information received, and the initiation of a treatment such as oxygen therapy.

Caregivers primarily in chronic diseases (so-called natural or informal caregivers) provide partial or total assistance to a dependent person for activities of daily living for care, social support and maintenance of autonomy, administrative procedures, psychological support, communication, domestic activities or even financial assistance, often despite their own exhaustion and health issues.

Recent studies on the QoL of patient-caregiver dyads in IPF through semi-structured interviews highlight the role of previously identified factors in caregivers as well.

Investigators want to confirm the data obtained in a large population of patients and their caregivers in order to evaluate the QoL of caregivers and confirm the impact of its various factors on it in order to suggest ways to improve the lives of both the caregiver and the patient.

The hypothesis of investigators' work is that the QoL of caregivers of patients with IPF is altered, particularly by the patient's functional symptoms (cough, dyspnea, fatigue, anxiety and depression), the arrival of oxygen therapy in the home and the caregiver's social isolation.

Investigators believe that there are links and interactions between the caregiver's and patient's quality of life and therefore have an impact on the patient's care.

Studieöversikt

Studietyp

Observationell

Inskrivning (Faktisk)

151

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Dijon, Frankrike
        • CHU Dijon Bourgogne

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Consultation at the Reference or Competence Centre for Rare Adult Lung Diseases

Beskrivning

Inclusion Criteria:

Patient inclusion criteria:

  • Patient rescruited from prevalent cases and incidents of patients with IPF according to the diagnostic criteria of the 2011 ATS/ERS/JRS/ALAT recommendations, for which a follow-up is planned or is in progress
  • Patient with a validated IPF diagnosis in multidisciplinary discussion in a Competence or Reference Centre. Regardless of the stage of the disease.
  • Patient who has not opposed their enrollment in the study
  • Adult patient
  • Patient able to be assessed every 6 months by principal investigator
  • A patient who can designate a non-professional primary caregiver regardless of kinship, age or involvement with the patient (the primary caregiver is defined as the person who works most frequently with the patient). Only one caregiver is retained per patient.
  • Patient with no memory or comprehension problems and able to read and write French

Caregiver Inclusion Criteria:

  • Caregiver designated by the patient as his or her primary caregiver
  • Caregiver who has not opposed their participation in the study
  • Adult caregiver
  • Caregiver with no comprehension problems and able to read and write in French
  • Caregiver with no memory problems

Exclusion Criteria:

  • Person subject to a measure of legal protection (curatorship, guardianship)
  • Person with a legal guardian
  • Adult unable to consent

Patient non-inclusion criteria:

  • Psychiatric, cognitive or neurological disorders making assessment impossible
  • Patient suffering from another medical condition considered severe by the investigator and which may interfere with the consequences of IVF (for example, active cancers, motor disability of neurological origin, osteo-articular diseases inducing dependence...)
  • Not likely to complete a self-administered questionnaire

Caregiver non-inclusion criteria:

  • Psychiatric, cognitive or neurological disorders making assessment impossible
  • Not likely to complete a self-administered questionnaire

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
patient-caregiver dyads
Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
Quality of life measurement at D0, M6 and M12 via the SF-36

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The generic quality of life score SF-36 to measure caregivers' quality of life
Tidsram: Through study completion, an average of 12 months
Measurement of caregivers' quality of life via the generic quality of life score SF-36 in each of the 8 dimensions of the component
Through study completion, an average of 12 months
The specific quality score CarGOQoL to measure caregivers' quality of life
Tidsram: Through study completion, an average of 12 months
Measurement of caregivers' quality of life via the specific quality score CarGOQoL in each of the 10 dimensions of the component
Through study completion, an average of 12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
"subjective burden" of caregivers
Tidsram: Through study completion, an average of 12 months
Measurement of the "subjective burden" of caregivers via the one-dimensional Zarit score
Through study completion, an average of 12 months
Patients' Quality of life
Tidsram: Through study completion, an average of 12 months
Measurement of patients' quality of life via the generic quality of life score SF-36 in each of the 8 dimensions
Through study completion, an average of 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 oktober 2019

Primärt slutförande (Faktisk)

28 september 2020

Avslutad studie (Faktisk)

15 december 2021

Studieregistreringsdatum

Först inskickad

22 juli 2019

Först inskickad som uppfyllde QC-kriterierna

23 juli 2019

Första postat (Faktisk)

24 juli 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 april 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 april 2022

Senast verifierad

1 april 2022

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • BELTRAMO FRSR 2018

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera